OREXIGEN THERAPEUTICS
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its lead combination product candidates include Contrave, which has completed Phase III clinical trials; and Empatic that has completed Phase II clinical trials. Contrave is a combination of two drugs, bupropion and naltrexone, in a sustained release formulation (SR). Bupropion is an antidepressant and smoking cessation medication; naltrexone is ... a treatment for alcohol and opioid addiction. The company's Empatic product candidate is a combination of bupropion SR and zonisamide SR. Zonisamide, in an immediate release formulation for the adjunctive treatment of partial seizures, a form of epilepsy. The company was founded in 2002 and is based in La Jolla, California.
OREXIGEN THERAPEUTICS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2002-01-01
Address:
La Jolla, California, United States
Country:
United States
Website Url:
http://www.orexigen.com
Total Employee:
101+
Status:
Active
Contact:
(858) 875-8600
Email Addresses:
[email protected]
Total Funding:
301 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Microsoft Exchange Online Amazon Office 365 Mail IPv6 Microsoft Azure DNS Microsoft Amazon Ohio Region
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
The Baupost Group
The Baupost Group investment in Post-IPO Equity - Orexigen Therapeutics
New Enterprise Associates
New Enterprise Associates investment in Post-IPO Equity - Orexigen Therapeutics
Wasatch Advisors
Wasatch Advisors investment in Series C - Orexigen Therapeutics
MPM Capital
MPM Capital investment in Series C - Orexigen Therapeutics
Montreux Equity Partners
Montreux Equity Partners investment in Series B - Orexigen Therapeutics
Morgenthaler Ventures
Morgenthaler Ventures investment in Series B - Orexigen Therapeutics
Duke University
Duke University investment in Series B - Orexigen Therapeutics
Domain Associates
Domain Associates investment in Series B - Orexigen Therapeutics
Greenspring Associates
Greenspring Associates investment in Series B - Orexigen Therapeutics
Scale Venture Partners
Scale Venture Partners investment in Series B - Orexigen Therapeutics
Official Site Inspections
http://www.orexigen.com
- Host name: 209.17.116.163
- IP address: 209.17.116.163
- Location: Jacksonville United States
- Latitude: 30.1426
- Longitude: -81.5727
- Metro Code: 561
- Timezone: America/New_York
- Postal: 32258
More informations about "Orexigen Therapeutics"
Orexigen Therapeutics - Wikipedia
Orexigen Therapeutics, Inc. is a public American pharmaceutical company focused on development of treatments for obesity. [1] The company is based in La Jolla, California and …See details»
Orexigen Therapeutics - Crunchbase Company Profile & Funding
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its lead combination product …See details»
Orexigen Therapeutics - LinkedIn
Biotechnology Innovation Organization Biotechnology Research Washington, DC Madrigal Pharmaceuticals ... Orexigen offers prospective employees exciting challenges, unique …See details»
Orexigen Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Mar 7, 2025 The partners plan to send out a questionnaire to members of the organization’s community to learn more about how they experience food noise.“We’ve heard from so many …See details»
Orexigen Therapeutics Careers and Employment | Indeed.com
Jan 12, 2020 Orexigen Therapeutics is a public American pharmaceutical company focused on development of treatments for obesity. The company is based in La Jolla, California and was …See details»
Orexigen announces strategic acquisition of all U.S. rights to …
Mar 15, 2016 Orexigen announces strategic acquisition of all U.S. rights to Contrave®, the market leading branded anti-obesity prescription medicine Acquisition magnifies projected long …See details»
Orexigen CEO Pledged To Keep Data Secret, But Not From Himself …
May 20, 2015 In an interview two years ago, Orexigen Chief Executive Mike Narachi understood that data from the largest clinical trial of his company’s weight loss drug Contrave were to be …See details»
Orexigen® Therapeutics Announces FDA Acceptance of …
Jun 1, 2010 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that...See details»
Orexigen Therapeutics, Inc. /Certain Assets/ - Drug pipelines, …
Explore Orexigen Therapeutics, Inc. /Certain Assets/ with its drug pipeline, therapeutic area, technology platform, .See details»
Time’s a-ticking for bankrupt Orexigen to sell off Contrave
Mar 12, 2018 Orexigen Therapeutics is filing for bankruptcy and plans to auction off its obesity med, Contrave, to pay down its debt. The San Diego-based company filed for a voluntary …See details»
Orexigen Therapeutics Ireland Ltd. (Orexigen Therapeutics Ireland …
100 项与 Orexigen Therapeutics Ireland Ltd. 相关的药物交易 登录后查看更多信息 100 项与 Orexigen Therapeutics Ireland Ltd. 相关的转化医学See details»
Orexigen Therapeutics, Inc. (OREX) 10K Annual Reports & 10Q SEC …
Inside Orexigen Therapeutics, Inc.'s 10-K Annual Report: Revenue - Product Highlight. For the year ended December 31, 2016, the Company recognized revenues under the Restated …See details»
Takeda and Orexigen Announce FDA Approval of Contrave® …
Sep 11, 2014 La Jolla, Calif.,and Osaka, Japan, September 11, 2014 - Takeda Pharmaceutical Company Limited (“Takeda”), its wholly-owned subsidiary Takeda Pharmaceuticals U.S.A., …See details»
Orexigen Therapeutics Announces New Drug Submission for …
Apr 25, 2017 Orexigen Contacts: Jason Keyes Chief Financial Officer Orexigen Therapeutics, Inc. +1-858-875-8600 [email protected] Erika Hackmann Y&R PR (Media Contact for …See details»
Takeda dumps weight loss med Contrave, leaving Orexigen in the …
Mar 16, 2016 The moment Orexigen investors have been dreading is here. On Tuesday, Takeda--the California drugmaker's marketing partner on obesity med Contrave--bade it …See details»
Pernix Therapeutics Buys Bankrupt Orexigen’s Weight Loss
Jul 31, 2018 In March, San Diego-based Orexigen Therapeutics filed for bankruptcy. Back in April, Orexigen entered into an asset purchase deal with Nalpropion Pharmaceuticals to sell …See details»
Sage Business Cases - Orexigen: Valuing Contrave - SAGE …
Jan 2, 2018 At the time, Orexigen had no products in the market, so all its hopes of financial success rested on this new treatment. Contrave had proven to be highly effective in clinical …See details»
Orexigen Valuing Contrave SWOT Analysis (10 Steps) - Strengths ...
Orexigen Valuing Contrave case help is dealing with increasing decline of Mexican Peso, which has resulted in declining of the financial performance. The business has absence of …See details»
Orexigen's post-Takeda plans for Contrave don't include 2016 …
May 13, 2016 The company has also partnered with contract sales organization inVentiv Health to help it staff those rep ranks, and through that partnership, Orexigen is confident it can “build …See details»
Orexigen Therapeutics Inc fka OREX Message Board - InvestorsHub
Find the latest discussion of Orexigen Therapeutics Inc fka OREX on iHub's community.See details»